108 related articles for article (PubMed ID: 2928903)
1. Lipid associated sialic acid in plasma in patients with advanced carcinoma of the ovaries.
Vardi JR; Tadros GH; Malhotra C; Charney T; Shebes M; Foemmel R
Surg Gynecol Obstet; 1989 Apr; 168(4):296-301. PubMed ID: 2928903
[TBL] [Abstract][Full Text] [Related]
2. Plasma lipid-associated sialic acid and serum CA 125 as indicators of disease status with advanced ovarian cancer.
Vardi JR; Tadros GH; Foemmel R; Shebes M
Obstet Gynecol; 1989 Sep; 74(3 Pt 1):379-83. PubMed ID: 2761915
[TBL] [Abstract][Full Text] [Related]
3. CA 125, NB/70K, and lipid-associated sialic acid in monitoring uterine papillary serous carcinoma.
Tseng PC; Sprance HE; Carcangiu ML; Chambers JT; Schwartz PE
Obstet Gynecol; 1989 Sep; 74(3 Pt 1):384-7. PubMed ID: 2761916
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer and family history: levels of lipid-associated sialic acid in plasma and absent family history of breast cancer in women who have breast tumors.
Brower ST; Tartter P; Weiss S; Luderer AA; Lehrer S
Mt Sinai J Med; 1995 Nov; 62(6):419-21. PubMed ID: 8692154
[TBL] [Abstract][Full Text] [Related]
5. [Serum lipid-associated sialic acid (LSA) in diagnosing and monitoring ovarian cancer].
Yue K; Bian M; Zhu D; Liu W; Siu S
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1995 Apr; 17(2):128-32. PubMed ID: 7656393
[TBL] [Abstract][Full Text] [Related]
6. Serum lipid-bound sialic acid as a tumoral marker in minimal residual tumors.
Musset M; Mathé G; Reizenstein P
Bull Soc Sci Med Grand Duche Luxemb; 1989; 126(1):17-20. PubMed ID: 2663215
[TBL] [Abstract][Full Text] [Related]
7. Tumor marker trends in asymptomatic women at risk for ovarian cancer: relevance for ovarian cancer screening.
Cane P; Azen C; Lopez E; Platt LD; Karlan BY
Gynecol Oncol; 1995 May; 57(2):240-5. PubMed ID: 7729742
[TBL] [Abstract][Full Text] [Related]
8. Correlation of platelet count with second-look laparotomy results and disease progression in patients with advanced epithelial ovarian cancer.
Bozkurt N; Yuce K; Basaran M; Kose F; Ayhan A
Obstet Gynecol; 2004 Jan; 103(1):82-5. PubMed ID: 14704249
[TBL] [Abstract][Full Text] [Related]
9. Acute phase reactants and circulating immune complexes in patients with ovarian carcinoma.
Dobryszycka W; Gerber J; Zuwała-Jagiełło J; Ujec M
Arch Immunol Ther Exp (Warsz); 1991; 39(1-2):41-50. PubMed ID: 1725104
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of serum sialic acid, heat stable alkaline phosphatase and fucose as markers of breast carcinoma.
Patel PS; Baxi BR; Adhvaryu SG; Balar DB
Anticancer Res; 1990; 10(4):1071-4. PubMed ID: 2382978
[TBL] [Abstract][Full Text] [Related]
11. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.
Baron AT; Lafky JM; Boardman CH; Balasubramaniam S; Suman VJ; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):129-37. PubMed ID: 10067810
[TBL] [Abstract][Full Text] [Related]
12. Correlation of serum sialic acid fractions as markers for carcinoma of the uterine cervix.
Lagana A; Martinez BP; Marino A; Fago G; Bizzarri M
Anticancer Res; 1995; 15(5B):2341-6. PubMed ID: 8572649
[TBL] [Abstract][Full Text] [Related]
13. Increase of serum lipid-associated sialic acid concentration in dogs with neoplasms.
Poli A; Arispici M; Camillo F; Corazza M
Am J Vet Res; 1986 Mar; 47(3):607-9. PubMed ID: 3754401
[TBL] [Abstract][Full Text] [Related]
14. [Tumor markers in the monitoring of ovarian cancer].
Xu SX
Zhonghua Fu Chan Ke Za Zhi; 1990 Nov; 25(6):345-7, 383. PubMed ID: 2282861
[TBL] [Abstract][Full Text] [Related]
15. Importance of serum sialic acid and lactate dehydrogenase in diagnosis and treatment monitoring of cervical cancer patients.
Patel PS; Rawal GN; Balar DB
Gynecol Oncol; 1993 Sep; 50(3):294-9. PubMed ID: 8406190
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
17. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
18. Negative laparoscopy is highly predictive of negative second-look laparotomy following chemotherapy for ovarian, tubal, and primary peritoneal carcinoma.
Littell RD; Hallonquist H; Matulonis U; Seiden MV; Berkowitz RS; Duska LR
Gynecol Oncol; 2006 Nov; 103(2):570-4. PubMed ID: 16769104
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients.
van Dalen A; Favier J; Burges A; Hasholzner U; de Bruijn HW; Dobler-Girdziunaite D; Dombi VH; Fink D; Giai M; McGing P; Harlozinska A; Kainz C; Markowska J; Molina R; Sturgeon C; Bowman A; Einarsson R
Gynecol Oncol; 2000 Dec; 79(3):444-50. PubMed ID: 11104617
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of water soluble and lipid soluble sialic acid levels as tumor markers.
Shamberger RJ
Anticancer Res; 1986; 6(4):717-20. PubMed ID: 3752951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
